Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study to Evaluate the Effect of Obicetrapib Alone and in Combination With Evolocumab (Repatha®) on Lipoprotein (a) in Patients With Mild Dyslipidemia: The VINCENT Study

Next Previous
Search
Trial Profile

A Phase 2 Study to Evaluate the Effect of Obicetrapib Alone and in Combination With Evolocumab (Repatha®) on Lipoprotein (a) in Patients With Mild Dyslipidemia: The VINCENT Study

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Evolocumab (Primary) ; Obicetrapib (Primary)
  • Indications Dyslipidaemias; Hyperlipoproteinaemia
  • Focus Therapeutic Use
  • Acronyms The VINCENT study
  • Sponsors NewAmsterdam Pharma

    • Most Recent Events

    • 10 Jan 2025 According to NewAmsterdam Pharma media release, The study is expected to complete in the second half of 2025 and to enroll 30 patients with baseline Lp(a) levels above 50 mg/dL.
    • 10 Jan 2025 According to NewAmsterdam Pharma media release, Data from Phase 2 VINCENT trial expected by 2H25.
    • 12 Nov 2024 Planned End Date changed from 1 Jul 2025 to 1 Dec 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top